Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07815418 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Relationship Between Novel Virological Indicators and Treatment With Different Nucleotide Analogues and the Prognosis of HBV-ACLF Patients

Name: The Relationship Between Novel Virological Indicators and Treatment With Different Nucleotide Analogues and the Prognosis of HBV-ACLF Patients — clinical trial record (NCT07815418)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhaseNot specified

SponsorTongji Hospital

Started2022-02-01

View on ClinicalTrials.gov ↗

Tongji Hospital

197 trials monitored

See 2 trials at risk

This is an observational study. This study mainly explores the dynamic changes of HBV RNA and HBcrAg during the treatment of HBV-ACLF, as well as the safety of entecavir (ETV), tenofovir alafenamide (TAF) and tenofovir amibufenamide (TMF) during the treatment process, and evaluates the differences in patient prognosis among the three drugs.

Trial Details

NCT Number	NCT07815418
Lead Sponsor	Tongji Hospital
Conditions	Acute-on-Chronic Liver Failure (ACLF), hepatitisB, Treatment
Enrollment	235 participants
Start Date	2022-02-01
Primary Completion	2024-04-01 (estimated)
Study Completion	2026-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-09-11